The importance of time: Grifols seeks biomarkers for early d...
Through a pioneering initiative called Chronos-PD, Grifols is partnering with the Michael J.
Roche taps Oxford BioTherapeutics for cancer drug discovery
Oxford BioTherapeutics has lined up another big pharma partner for its drug discovery platform, signing a $1bn deal with oncology giant Roche.
Google promises new AI models for drug discovery
Google has said it will release new open-source AI models for drug discovery, TxGemma, through a developers' programme later this month.
J&J's nipocalimab fast-tracked for Sjogren's disease
Johnson & Johnson's FcRn inhibitor nipocalimab has been awarded fast-track status by the FDA as a treatment for Sjogren's disease.
Latest News
Views & Analysis
Deep Dive
White Papers & Webinar
Podcasts & Video
Partner Content
2nd GLP-1-Based Therapeutics Summit
If you thought that 2024 was the year for GLP-1 Agonists, then hold on for 2025!
5th Inner Ear Disorders Therapeutics Summit
Coined by industry as the only meeting of its kind, uniquely positioned to share fresh ideas and assess viable approaches to your most pressing preclinical, translational, and clin
Return to Europe for the 2nd IMPACCT Real World Evidence Sum...
The IMPACCT Real World Evidence Summit is back, offering the opportunity to bring together 50+ pharma RWE decision makers to discuss integrated evidence plans, data sharing optimization, infrastruc
4th Circular & Self-Amplifying RNA Therapeutics Summit
With CSL Seqirus and Arcturus Therapeutics successfully developing the first approved self-amplifying RNA vaccine, the field of next generation RNAs celebrates the potential of circular and self-am
4th World ADC Asia Summit
Kickstart Your 2025 ADC Development at the 4th World ADC Asia Summit